Back

Clinical impact of frailty after durable left ventricular assist device implantation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Progress in advanced heart failure therapy Ventricular Assist Devices ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Shingo Kazama

Nagoya University Graduate School of Medicine, Nagoya (Japan)

5 More presentations in this session

Presentation thumbnail
Equivalent improvement in exercise capacity after mechanical circulatory support compared to heart transplant in advanced heart failure
Doctor H. Lo (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Impact of HF pharmacological therapy on the durability of favorable response after LVAD weaning: a VAD wean registry analysis
Doctor S. Drakos (Salt Lake City, US)
Abstract Slides Video
Presentation thumbnail
Frailty and obesity in heart transplant recipients: impact on post-transplant mortality
Doctor T. Goubar (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Impact of delayed heparin bridging on bleeding and stroke after heartmate 3 left ventricular assist device implantation
Mr P. Jahangiri (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of antithrombotic regimens in patients with durable left ventricular assist devices: a systematic review and bayesian network meta-analysis
Ms M. Ramos Miranda (BR)
Abstract Slides Video

Access the full session

Session thumbnail
Progress in advanced heart failure therapy
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Prognostic value of machine learning-based automated frailty rating in elderly patients with chronic heart failure
thumbnail
Congress Presentation
Frailty and bleeding events in patients with heart failure: Insights from the JROADHF-NEXT
thumbnail
Congress Presentation
Multiple comorbidities are associated with poor prognosis in patients with ADHF-HFpEF and non-frailty or mild frailty but not moderate-severe frailty -PURSUIT-HFpEF Registry-

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources